Login to Your Account



Would-Be Gap Fillers Line Up

Itching for the Niche: Genzyme Woes Put Others High on LSDs

By Randy Osborne


Monday, September 28, 2009
Protalix Therapeutics Inc.'s finish of the pivotal Phase III trial with prGCD, a plant cell-expressed recombinant form of glucocerebrosidase for Gaucher's disease, put hot breath on the neck of Genzyme Corp., still grappling with problems brought about by a virus discovered in one of the reactors used to make its therapy.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription